INGN Inogen Inc
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1294133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.7%
TTM net income YoY-39.7%
TTM EPS YoY-32.0%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR—
Margins
Gross margin39.6%
Operating margin-10.4%
Net margin-9.3%
FCF margin-3.0%
EBITDA margin-4.2%
Returns
ROE-20.0%
ROA-12.4%
ROIC (approx.)-37.5%
Asset turnover1.33x
Leverage & solvency
Liabilities / assets40.7%
Debt / equity0.00x
Current ratio2.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.26x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $77.19M | $95.08M | $85.11M | $121.94M | $79.09M | $92.28M | $82.28M | $80.08M |
| Cost of revenue | $43.19M | $51.81M | $47.25M | $69.93M | $42.92M | $50.94M | $45.91M | $43.79M |
| Gross profit | $34.01M | $43.27M | $37.86M | $35.24M | $36.16M | $41.34M | $36.37M | $36.29M |
| R&D expense | $5.40M | $5.87M | $5.10M | $5.32M | $4.84M | $5.21M | $4.03M | $5.90M |
| SG&A expense | $14.74M | $17.67M | $17.50M | $16.12M | $16.13M | $16.87M | $16.24M | $17.62M |
| Operating income | -$15.58M | -$5.10M | -$9.34M | -$9.31M | -$5.43M | -$6.13M | -$7.66M | -$11.39M |
| Pretax income | -$14.64M | -$4.00M | -$8.50M | -$9.81M | -$3.76M | -$4.30M | -$6.27M | -$10.09M |
| Income tax | $153,000 | -$154,000 | -$174,000 | -$236,000 | -$146,000 | -$153,000 | -$97,000 | -$330,000 |
| Net income | -$16.16M | -$3.85M | -$8.32M | -$7.13M | -$5.29M | -$4.15M | -$6.17M | -$9.76M |
| EBITDA | -$14.71M | -$1.65M | -$4.43M | $4.74M | -$4.46M | -$2.12M | -$2.47M | -$6.31M |
| EPS (basic) | -0.61 | -0.14 | -0.30 | — | -0.20 | -0.15 | -0.25 | — |
| EPS (diluted) | -0.61 | -0.14 | -0.30 | — | -0.20 | -0.15 | -0.25 | — |
| Weighted avg. shares (diluted) | 26.46M | 27.05M | 27.32M | — | 27.08M | 26.96M | 25.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $81.84M | $87.28M | $93.11M | $103.73M | $106.48M | $103.69M | $118.89M | $113.80M |
| Short-term investments | $15.00M | $18.26M | $17.06M | $15.85M | $16.75M | $18.75M | — | $0 |
| Receivables | $48.61M | $46.16M | $41.87M | $34.14M | $40.37M | $38.59M | $36.62M | $29.56M |
| Inventory | $29.04M | $28.63M | $24.99M | $25.97M | $25.07M | $24.31M | $26.27M | $24.81M |
| Current assets | $208.32M | $194.14M | $190.66M | $224.60M | $203.72M | $203.12M | $200.71M | $185.45M |
| PP&E, net | $8.62M | $31.78M | $33.69M | $10.06M | $37.33M | $40.17M | $41.10M | $44.40M |
| Goodwill | $0 | $10.39M | $10.48M | $10.70M | $10.70M | $10.70M | $9.86M | $9.46M |
| Intangibles | $26.08M | $27.45M | $28.91M | $30.76M | $32.05M | $33.36M | $31.61M | $30.49M |
| Total assets | $264.91M | $285.57M | $285.93M | $298.62M | $307.01M | $312.04M | $308.41M | $296.19M |
| Current liabilities | $70.27M | $70.86M | $61.45M | $63.53M | $64.94M | $67.07M | $65.45M | $76.69M |
| Total liabilities | $107.92M | $110.71M | $103.02M | $106.39M | $109.83M | $112.55M | $110.46M | $122.33M |
| Shareholders' equity | $156.99M | $174.86M | $182.91M | $192.23M | $197.18M | $199.49M | $197.95M | $173.86M |
| Shares outstanding | 26.20M | 26.73M | 27.37M | 27.23M | 27.15M | 27.04M | 26.89M | 23.90M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.47M | $2.95M | -$6.68M | -$943,000 | $2.17M | $4.35M | -$16.79M | -$3.02M |
| Capital expenditure | $280,000 | $711,000 | $210,000 | $979,000 | $568,000 | $684,000 | $292,000 | $329,000 |
| Free cash flow | -$4.75M | $2.23M | -$6.89M | -$1.92M | $1.60M | $3.67M | -$17.08M | -$3.35M |
| Investing cash flow | $2.19M | -$3.13M | -$1.98M | -$1.52M | -$82,000 | -$22.57M | -$2.04M | $11.54M |
| Financing cash flow | -$3.44M | -$5.62M | -$2.12M | -$187,000 | $418,000 | $0 | $23.95M | -$260,000 |
| Depreciation & amortization | $876,000 | $3.44M | $4.90M | $14.05M | $970,000 | $4.01M | $5.19M | $5.08M |
| Stock-based compensation | $1.76M | $1.77M | $1.95M | $1.81M | $1.74M | $2.29M | $2.15M | $1.69M |
| Share buybacks | $3.75M | $5.62M | $1.87M | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.